Skip to content
10-Q

Quarterly Report

BRAINSTORM CELL THERAPEUTICS INC. BCLI

0001104659-26-062648

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 11.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 11.03M sh
Shares Diluted Q1 2026 · Mar 31, 2025 6.34M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.32M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.63M
Short Term Debt Q1 2026 · Mar 31, 2026 $1.33M
Short Term Debt Q1 2026 · Dec 31, 2025 $967K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $15K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $29K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$11.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$9.99M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$7.46M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$7.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.76M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.01M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.76M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.01M
Current Assets Q1 2026 · Mar 31, 2026 $184K
Current Assets Q1 2026 · Dec 31, 2025 $307K
Total Assets Q1 2026 · Mar 31, 2026 $755K
Total Assets Q1 2026 · Dec 31, 2025 $1.02M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.19
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.45
Eps Basic Q1 2026 · Mar 31, 2026 −$0.19
Eps Basic Q1 2026 · Mar 31, 2025 −$0.45
Sga Expense Q1 2026 · Mar 31, 2026 $1.28M
Sga Expense Q1 2026 · Mar 31, 2025 $1.79M
Rd Expense Q1 2026 · Mar 31, 2026 $762K
Rd Expense Q1 2026 · Mar 31, 2025 $1.3M
Net Income Q1 2026 · Mar 31, 2026 −$2.13M
Net Income Q1 2026 · Mar 31, 2025 −$2.86M
Operating Income Q1 2026 · Mar 31, 2026 −$2.05M
Operating Income Q1 2026 · Mar 31, 2025 −$3.09M